E. Morra

Prognostic Impact of C-Kit Mutations in Core Binding Factor-Leukemia.

A. Cuneo, G. Nadali, R. Cairoli, 2004 .

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.

Alessandro Beghini, Enrica Morra, Andrea Biondi, 2004, Haematologica.

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

G. Specchia, M. Gobbi, R. Fanin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia

M. Zago, A. Savoia, J. Elion, 1998 .

Chronic myelogenous leukemia and exposure to ionizing radiation — a retrospective study of 443 patients

E. Morra, M. Lazzarino, C. Astori, 1995, Annals of Hematology.

RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia.

P. Peterlongo, R. Cairoli, E. Morra, 2000, Human molecular genetics.

Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

V. Zagonel, L. Arcaini, E. Morra, 2000, Therapeutic drug monitoring.

A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia.

M. Mancini, R. Foà, F. Mandelli, 2000, Blood.

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

V. Petrizzi, E. Vismara, M. Montillo, 2011, Blood.